Zobrazeno 1 - 10
of 48
pro vyhledávání: '"NOBUYUKI MUROI"'
Autor:
Akihiko Futamura, Takenao Koseki, Junichi Iida, Akito Suzuki, Nobuyuki Muroi, Michiaki Myotoku, Hiroki Maki, Kazuhisa Mizutani, Hikaru Ogino, Yasuki Taniguchi, Keiichiro Higashi, Masanobu Usui
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract Background This study aimed to clarify the effectiveness of nutrition support team (NST) facilities for preventing central line-associated bloodstream infection (CLABSI). Methods We retrospectively analyzed the incidence of CLABSI as well as
Externí odkaz:
https://doaj.org/article/16cc7ee9272b4420887f68941867a4be
Autor:
Ryo Tamura, Kei Irie, Atsushi Nakagawa, Hirohito Muroi, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Shoji Fukushima, Keisuke Tomii, Tohru Hashida
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 4, Pp 513-521 (2023)
Abstract Although remdesivir, a prodrug of nucleoside analog (GS‐441524), has demonstrated clinical benefits in coronavirus disease 2019 (COVID‐19) treatment, its pharmacokinetics (PKs) in patients with COVID‐19 remain poorly understood. Theref
Externí odkaz:
https://doaj.org/article/81089085c39e4fd985767e9beedfdef0
Autor:
Tomoki Takase, Norio Masumoto, Naoki Shibatani, Yusaku Matsuoka, Fumiaki Tanaka, Masaki Hirabatake, Hiroko Kashiwagi, Itaru Nishioka, Hiroaki Ikesue, Tohru Hashida, Naoshi Koide, Nobuyuki Muroi
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract Background Although automated dispensing robots have been implemented for medication dispensing in Japan, their effect is yet to be fully investigated. In this study, we evaluated the effect of automated dispensing robots and collaborative w
Externí odkaz:
https://doaj.org/article/40513c96088f44bd89a652f9678fb899
Autor:
Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Shoji Fukushima, Keisuke Tomii, Tohru Hashida
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1161-1170 (2021)
Abstract The antiretroviral drug favipiravir (FPV) inhibits RNA‐dependent RNA polymerase. It has been developed for the treatment of the novel coronavirus (severe acute respiratory syndrome coronavirus 2) infection disease, coronavirus disease 2019
Externí odkaz:
https://doaj.org/article/6c5ca5eb90e3475d8bea707a688b3f02
Autor:
Kanae Yamashita, Yoshimitsu Shimomura, Hiroaki Ikesue, Nobuyuki Muroi, Akihiro Yoshimoto, Tohru Hashida
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Pneumocystis pneumonia (PCP) is a potentially life-threatening infection. Trimethoprim-sulfamethoxazole (TMP-SMX) is considered as the first regimen for PCP prophylaxis according to several guidelines. The recommended prophylactic
Externí odkaz:
https://doaj.org/article/5886d46695894a43ba44343af8746c96
Autor:
Fumiaki Tanaka, Naoki Shibatani, Kazumi Fujita, Hiroaki Ikesue, Satoru Yoshimizu, Nobuyuki Muroi, Yasuo Kurimoto, Tohru Hashida
Publikováno v:
Journal of Pharmaceutical Health Care and Sciences, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract Background Primary angle closure disease (PACD) is a type of glaucoma in which the intraocular pressure (IOP) is increased because of the blockage of the anterior chamber angle. Medications contraindicated for patients with PACD, such as ant
Externí odkaz:
https://doaj.org/article/ee5c5caf4e6841ee9e836248486475ef
Autor:
Masaki Hirabatake, Hiroaki Ikesue, Yuna Iwama, Kei Irie, Shintaro Yoshino, Toshinari Yamasaki, Tohru Hashida, Mutsushi Kawakita, Nobuyuki Muroi
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Background: Enzalutamide is useful for the treatment of castration-resistant prostate cancer (CRPC). Despite its usefulness, adverse events (AEs) sometimes force patients to discontinue treatment. To maximize patient care, we developed an ambulatory
Externí odkaz:
https://doaj.org/article/d4adec176ad2486aac5b1e8f54b9d8ad
Autor:
Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Keisuke Tomii, Tohru Hashida
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 5, Pp 880-885 (2020)
Since December 2019, a novel coronavirus (severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2)) infection has been rapidly spreading worldwide and causing the respiratory illness, coronavirus disease 2019 (COVID‐19). The antiretrovira
Externí odkaz:
https://doaj.org/article/27c0f02a984440fc840526bf958cb16f
Autor:
Kenta Yamaoka, Masaki Fujiwara, Mayako Uchida, Yoshihiro Uesawa, Nobuyuki Muroi, Tadashi Shimizu
Publikováno v:
Life, Vol 12, Iss 9, p 1355 (2022)
Poly (ADP-ribose) polymerase (PARP) inhibitors are effective against breast cancer susceptibility gene (BRCA) mutations. Clinical trials have reported hematologic toxicity and gastrointestinal symptoms as class effects of PARP inhibitors. However, in
Externí odkaz:
https://doaj.org/article/e4e19e853cd34a2185afb6534ab12f6e
Autor:
Yukari Satsuma, Hiroaki Ikesue, Kaori Kusuda, Mami Maeda, Nobuyuki Muroi, Ryobu Mori, Mariko Kogo, Ryosuke Hirabayashi, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii, Tohru Hashida
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Background: Pirfenidone is an anti-fibrotic agent used to treat patients with idiopathic pulmonary fibrosis (IPF). Managing adverse drug events and ensuring compliance with pirfenidone treatment for a prolonged period are important to reduce the rate
Externí odkaz:
https://doaj.org/article/7b917075f63945708504f33124da4092